Notice Pursuant to the National Cooperative Research and Production Act of 1993-Cooperative Research Group on CHEDE-VII, 58653-58654 [2017-26890]
Download as PDF
<![CDATA[
Federal Register / Vol. 82, No. 238 / Wednesday, December 13, 2017 / Notices
sradovich on DSK3GMQ082PROD with NOTICES
Commission Rule 210.2 (19 CFR 210.2),
without a formal hearing or discovery.
Epson filed a timely response opposing
the request. Thereafter, Requesters filed
a motion for leave to file a reply to
Epson’s response.
On June 16, 2017, the Commission
determined to institute a consolidated
advisory opinion proceeding in both
investigations and referred the request
to the Chief ALJ to designate a presiding
ALJ. 82 FR 27723 (Jun. 16, 2017). Epson,
the Requesters, and OUII were named as
parties to the proceeding. The
Commission also determined to deny
Requesters’ motion for leave to file a
reply.
On November 17, 2017, Epson and the
Requesters filed a joint motion to
terminate the consolidated advisory
opinion proceeding based on a
settlement agreement. The joint motion
included a confidential version of the
settlement agreement. A public version
of the agreement was filed with the
public version of the joint motion. That
same day, OUII filed a response in
support of the joint motion. On
November 22, 2017, the ALJ issued the
subject ID (Order No. 6) granting the
joint motion to terminate the
consolidated advisory opinion
proceeding. No petitions for review
were filed.
The Commission has determined not
to review the subject ID. The
Commission agrees with the ALJ that
the joint motion to terminate the
consolidated advisory opinion
proceeding complies with the
Commission’s rules for termination and
that there is no evidence that
termination of the proceeding will
adversely affect the public interest.
Order No. 6 at 2–3.
The authority for the Commission’s
determination is contained in section
337 of the Tariff Act of 1930, as
amended (19 U.S.C. 1337), and in part
210 of the Commission’s Rules of
Practice and Procedure (19 CFR part
210).
By order of the Commission.
Dated: December 7, 2017.
William R. Bishop,
Supervisory Hearings and Information
Officer.
[FR Doc. 2017–26826 Filed 12–12–17; 8:45 am]
BILLING CODE 7020–02–P
VerDate Sep<11>2014
18:53 Dec 12, 2017
Jkt 244001
JUDICIAL CONFERENCE OF THE
UNITED STATES
Hearings of the Judicial Conference
Advisory Committees on the Federal
Rules of Appellate and Criminal
Procedure and Rules of Evidence
Advisory Committees on the
Federal Rules of Appellate and Criminal
Procedure, and Rules of Evidence,
Judicial Conference of the United States.
ACTION: Notice of cancellation of public
hearings.
AGENCY:
The January 5, 2018 public
hearings in Phoenix, Arizona, on
proposed amendments to the Appellate,
Criminal and Evidence Rules, the Rules
Governing Section 2254 Cases in the
United States District Courts, and the
Rules Governing Section 2255
Proceedings for the United States
District Courts have been canceled.
FOR FURTHER INFORMATION CONTACT:
Rebecca A. Womeldorf, Rules
Committee Secretary, Rules Committee
Staff, Administrative Office of the
United States Courts, Washington, DC
20544, telephone (202) 502–1820.
SUPPLEMENTARY INFORMATION:
Announcement for this hearing was
previously published in 82 FR 37610.
SUMMARY:
Dated: December 7, 2017.
Rebecca A. Womeldorf,
Rules Committee Secretary.
58653
Also, ArcSoft Inc., Freemont, CA;
ASD Electronics, Kowloon, HONG
KONG–CHINA; EDC GmbH,
Langenhagen, GERMANY; Orion
Electric Co., Ltd., Fukui, JAPAN; Pixela
Corporation, Osaka, JAPAN; TEAC
Corporation, Tokyo, JAPAN; and
Yamaha Corporation, Hamamatsu,
JAPAN, have withdrawn as parties to
this venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and DVD CCA
intends to file additional written
notifications disclosing all changes in
membership.
On April 11, 2001, DVD CCA filed its
original notification pursuant to Section
6(a) of the Act. The Department of
Justice published a notice in the Federal
Register pursuant to Section 6(b) of the
Act on August 3, 2001 (66 FR 40727).
The last notification was filed with
the Department on August 23, 2017. A
notice was published in the Federal
Register pursuant to Section 6(b) of the
Act on September 29, 2017 (82 FR
45611).
Patricia A. Brink,
Director of Civil Enforcement, Antitrust
Division.
[FR Doc. 2017–26891 Filed 12–12–17; 8:45 am]
BILLING CODE P
[FR Doc. 2017–26789 Filed 12–12–17; 8:45 am]
DEPARTMENT OF JUSTICE
BILLING CODE 2210–55–P
Antitrust Division
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—DVD Copy Control
Association
Notice is hereby given that, on
November 21, 2017, pursuant to Section
6(a) of the National Cooperative
Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (‘‘the Act’’), DVD
Copy Control Association (‘‘DVD CCA’’)
has filed written notifications
simultaneously with the Attorney
General and the Federal Trade
Commission disclosing changes in its
membership. The notifications were
filed for the purpose of extending the
Act’s provisions limiting the recovery of
antitrust plaintiffs to actual damages
under specified circumstances.
Specifically, Cinram GmbH, Oliphant,
PA; Kaleidescape, Inc., Mountain View,
CA; and Lite-On Technology Corp.,
Taipei, TAIWAN, have been added as
parties to this venture.
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Cooperative Research
Group on CHEDE–VII
Notice is hereby given that, on
November 8, 2017, pursuant to Section
6(a) of the National Cooperative
Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (‘‘the Act’’),
Southwest Research Institute—
Cooperative Research Group on
CHEDE–VII (‘‘CHEDE–VII’’) has filed
written notifications simultaneously
with the Attorney General and the
Federal Trade Commission disclosing
changes in its membership. The
notifications were filed for the purpose
of extending the Act’s provisions
limiting the recovery of antitrust
plaintiffs to actual damages under
specified circumstances. Specifically,
General Motors, Detroit, MI, has
withdrawn as a party to this venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
E:\FR\FM\13DEN1.SGM
13DEN1
58654
Federal Register / Vol. 82, No. 238 / Wednesday, December 13, 2017 / Notices
project remains open, and CHEDE–VII
intends to file additional written
notifications disclosing all changes in
membership.
On January 6, 2016, CHEDE–VII filed
its original notification pursuant to
Section 6(a) of the Act. The Department
of Justice published a notice in the
Federal Register pursuant to Section
6(b) of the Act on February 2, 2016, (81
FR 5484).
The last notification was filed with
the Department on February 13, 2017. A
notice was published in the Federal
Register pursuant to section 6(b) of the
Act on March 27, 2017, (82 FR 15239).
Patricia A. Brink,
Director of Civil Enforcement, Antitrust
Division.
[FR Doc. 2017–26890 Filed 12–12–17; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: VHG Labs DBA LGC
Standard Warehouse
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes and applicants
therefore, may file written comments on
or objections to the issuance of the
proposed registration on or before
January 12, 2018. Such persons may
also file a written request for a hearing
on the application on or before January
12, 2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All request for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
DATES:
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DRW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix of subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on April
4, 2017, VHG LABS DBA LGC Standards
Warehouse, 3 Perimeter Road,
Manchester, New Hampshire 03103
applied to be registered as an importer
of the following basic classes of
controlled substances:
sradovich on DSK3GMQ082PROD with NOTICES
Controlled substance
Drug code
3-Fluoro-N-methylcathinone (3-FMC) ..............................................................................................................................
Cathinone ........................................................................................................................................................................
Methcathinone .................................................................................................................................................................
4-Fluoro-N-methylcathinone (4-FMC) ..............................................................................................................................
Pentedrone (a-methylaminovalerophenone) ...................................................................................................................
Mephedrone (4-Methyl-N-methylcathinone) ....................................................................................................................
4-Methyl-N-ethylcathinone (4-MEC) ................................................................................................................................
Naphyrone .......................................................................................................................................................................
N-Ethylamphetamine .......................................................................................................................................................
N,N-Dimethylamphetamine ..............................................................................................................................................
Fenethylline .....................................................................................................................................................................
4-Methylaminorex (cis isomer) ........................................................................................................................................
Methaqualone ..................................................................................................................................................................
Mecloqualone ..................................................................................................................................................................
JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl) indole) ...................................................................................................
SR-18 (Also known as RCS-8) (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl) indole) .................................................
5-Flouro-UR-144 and XLR11 [1-(5-Fluoro-pentyl)1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone .................
AB-FUBINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) ......................
JWH-019 (1-Hexyl-3-(1-naphthoyl)indole) .......................................................................................................................
ADB-PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) ..................................
APINACA and AKB48 N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide ..............................................................
JWH-081 (1-Pentyl-3-(1-(4-methoxynaphthoyl) indole) ...................................................................................................
SR-19 (Also known as RCS-4) (1-Pentyl-3-[(4-methoxy)-benzoyl] indole ......................................................................
JWH-018 (also known as AM678) (1-Pentyl-3-(1-naphthoyl)indole) ..............................................................................
JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl) indole) ......................................................................................................
UR-144 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone ..................................................................
JWH-073 (1-Butyl-3-(1-naphthoyl)indole) ........................................................................................................................
JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole) ...........................................................................................
AM2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl) indole) .......................................................................................................
JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl) indole) ......................................................................................................
PB-22 (Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate) ..................................................................................................
5F-PB-22 (Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate) ..............................................................................
Alpha-ethyltryptamine ......................................................................................................................................................
Ibogaine ...........................................................................................................................................................................
CP-47,497 (5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl-phenol) .................................................................
CP-47,497 C8 Homologue (5-(1,1-Dimethyloctyl)-2-[(1R,3S)3-hydroxycyclohexyl-phenol) ...........................................
VerDate Sep<11>2014
18:53 Dec 12, 2017
Jkt 244001
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
E:\FR\FM\13DEN1.SGM
13DEN1
1233
1235
1237
1238
1246
1248
1249
1258
1475
1480
1503
1590
2565
2572
6250
7008
7011
7012
7019
7035
7048
7081
7104
7118
7122
7144
7173
7200
7201
7203
7222
7225
7249
7260
7297
7298
Schedule
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
]]>Agencies
[Federal Register Volume 82, Number 238 (Wednesday, December 13, 2017)]
[Notices]
[Pages 58653-58654]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-26890]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993--Cooperative Research Group on CHEDE-VII
Notice is hereby given that, on November 8, 2017, pursuant to
Section 6(a) of the National Cooperative Research and Production Act of
1993, 15 U.S.C. 4301 et seq. (``the Act''), Southwest Research
Institute--Cooperative Research Group on CHEDE-VII (``CHEDE-VII'') has
filed written notifications simultaneously with the Attorney General
and the Federal Trade Commission disclosing changes in its membership.
The notifications were filed for the purpose of extending the Act's
provisions limiting the recovery of antitrust plaintiffs to actual
damages under specified circumstances. Specifically, General Motors,
Detroit, MI, has withdrawn as a party to this venture.
No other changes have been made in either the membership or planned
activity of the group research project. Membership in this group
research
[[Page 58654]]
project remains open, and CHEDE-VII intends to file additional written
notifications disclosing all changes in membership.
On January 6, 2016, CHEDE-VII filed its original notification
pursuant to Section 6(a) of the Act. The Department of Justice
published a notice in the Federal Register pursuant to Section 6(b) of
the Act on February 2, 2016, (81 FR 5484).
The last notification was filed with the Department on February 13,
2017. A notice was published in the Federal Register pursuant to
section 6(b) of the Act on March 27, 2017, (82 FR 15239).
Patricia A. Brink,
Director of Civil Enforcement, Antitrust Division.
[FR Doc. 2017-26890 Filed 12-12-17; 8:45 am]
BILLING CODE P
